ASCO25: Roche’s Itovebi combo reduces risk of death in breast cancer by 33%
Roche published an abstract containing the data ahead of a presentation at the American Society of Clinical Oncology’s (ASCO) 2025. Credit: Taljat David via Shutterstock. Roche’s blockbuster vision for phosphoinositide 3-kinase (PI3K inhibitor) Itovebi (inavolisib) has been dealt a boost […]
ASCO25: Roche’s Itovebi combo reduces risk of death in breast cancer by 33% Read More »